Expertise in
8
conditions

Natsumi Inoue

Kanazawa, JP 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Kanazawa, JP 

Overview

Natsumi Inoue practices practicing medicine in Kanazawa, Japan.

Ms. Inoue is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Juvenile Idiopathic Arthritis (JIA), Polyarteritis Nodosa, Henoch-Schonlein Purpura, and Vasculitis.

She is actively involved in clinical research, co-authoring 60 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Kanazawa, 9208640, Japan
Other Locations
Sapporo, 0600810, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: August 24, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

60 Total Publications

First-Line Tocilizumab Monotherapy for Juvenile Systemic Sclerosis With Interstitial Lung Disease: A Case Report.
First-Line Tocilizumab Monotherapy for Juvenile Systemic Sclerosis With Interstitial Lung Disease: A Case Report.
Journal: Case reports in rheumatology
Published: April 05, 2026

Frequently Asked Questions about Natsumi Inoue

Is Natsumi Inoue a top-rated expert for Juvenile Idiopathic Arthritis (JIA)?

MediFind is an objective health platform that identifies experts based on real-world data. Natsumi Inoue is classified as an Distinguished expert for Juvenile Idiopathic Arthritis (JIA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Natsumi Inoue participate in research or clinical trials?

Yes. Natsumi Inoue has published 60 articles and abstracts on conditions like Juvenile Idiopathic Arthritis (JIA). You can view a list of Natsumi Inoue's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Inoue's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 46 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile